Apr 08, 2021 8:00am EDT NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases
Mar 16, 2021 8:00am EDT NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference
Mar 09, 2021 7:00am EST NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021
Feb 11, 2021 4:01pm EST NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021
Jan 28, 2021 8:00am EST NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics
Jan 11, 2021 6:00am EST NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Dec 23, 2020 4:05pm EST NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020
Dec 16, 2020 6:30am EST NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1
Dec 02, 2020 8:00am EST NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer